AbbVie Stock Dips Amid White House News Despite Strong Q2 Earnings
AbbVie shares retreated slightly in Thursday trading after WHITE House demands overshadowed robust quarterly results. The pharmaceutical giant posted $15.4 billion in Q2 revenue, a 7% year-over-year increase, driven by blockbuster drugs Skyrizi (+62%) and Rinvoq (+42%). Adjusted earnings of $2.97/share beat analyst estimates.
While Humira sales continued declining due to biosimilar competition (-58%), the company raised full-year adjusted EPS guidance to $11.88-$12.08. The late-session pullback mirrored broader market trends, demonstrating how macro-political factors can override strong fundamentals.